NCT04523181: A trial that was reported late by Golden Biotechnology Corporation
This trial has reported, although it was 264 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04523181 |
|---|---|
| Title | A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 15, 2020 |
| Completion date | Dec. 23, 2021 |
| Required reporting date | Dec. 23, 2022, midnight |
| Actual reporting date | Sept. 13, 2023 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 264 |